Conditions: Gastric Cancer
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 53
Healthy volunteers: no

Brief summary:
Study H3E-MW- S108 is a multicenter, single arm, open-label Phase 2 study to determine the response rate of pemetrexed plus cisplatin in patients with Stage IV gastric cancer, not amenable to curative surgery, or recurrence after prior surgery, who have had no prior chemotherapy. It was planned to enroll approximately 50 patients who qualified for tumor response population.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: pemetrexed intervention 2: cisplatin
Intervention descriptions: intervention 1: 700 milligrams/meters squared (mg/m2), intravenous (IV), every 21 days x 6 cycles intervention 2: 75 mg/m2, IV, every 21 days x 6 cycles

Protocol document: